SER 100

Drug Profile

SER 100

Alternative Names: SER-100; SER100 PH; SER100 TR-ISH; ZP-120

Latest Information Update: 16 Jan 2016

Price : $50

At a glance

  • Originator Zealand Pharma
  • Developer Serodus; Zealand Pharma
  • Class Oligopeptides; Peptides
  • Mechanism of Action Nociceptin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Isolated systolic hypertension
  • Phase I Pulmonary hypertension
  • Discontinued Decompensated heart failure

Most Recent Events

  • 16 Jan 2016 Phase-I clinical trials in Pulmonary hypertension (In volunteers) in Norway (IV) before January 2016
  • 09 Sep 2014 Efficacy and adverse events data from a phase IIa trial in Isolated systolic hypertension released by Serodus
  • 01 Sep 2014 Serodus completes a phase IIa trial in Isolated systolic hypertension (Treatment-resistant, In the elderly) in Finland, Hungary, Norway and United Kingdom (NCT01987284)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top